重新评估危重患儿使用质子泵抑制剂与组胺-2受体拮抗剂:系统综述与Meta分析
应激性溃疡预防未显著降低消化道出血风险或缩短PICU住院时长,但观察性研究提示其与院内肺炎和死亡风险增加相关,尚需临床试验验证。
要点
- 应激性溃疡预防未显著降低PICU患儿消化道出血风险(MHRD 5.0%,95%CI -1.0%至11.0%)。
- 接受应激性溃疡预防的患儿院内肺炎风险增加(MHRD 5.3%,95%CI 3.5%-7.0%)。
- 死亡风险增加(MHRD 2.1%,95%CI 2.0%-2.2%),但剔除一项大型研究后该关联不再存在。
核心结论
- 应激性溃疡预防在减少消化道出血或缩短PICU住院时长方面未显示明确获益。
- 观察性研究提示应激性溃疡预防与院内肺炎和死亡风险增加相关,尚需临床试验验证。
研究设计与样本
- 采用随机效应Mantel-Haenszel风险差异(MHRD)模型合并所有选定研究进行Meta分析。
主要发现
- 消化道出血总体发生率为15.2%。
- 基于应激性溃疡预防状态,消化道出血风险无差异(MHRD 5.0%;95%CI -1.0%至11.0%;I2=62%)。
- 接受应激性溃疡预防的患者较未接受者院内肺炎风险增加(MHRD 5.3%;95%CI 3.5%-7.0%;I2=0%)。
- 接受应激性溃疡预防的患者死亡风险增加(MHRD 2.1%;95%CI 2.0%-2.2%;I2=0%),但剔除一项大型研究后敏感性分析未再发现该关联。
- 两组间PICU住院时长无统计学显著差异(标准化均数差0.42天;95%CI -0.16至1.01天;I2=89.8%)。
关键数值与推荐
- 主要结局为消化道出血和院内肺炎的发生率。
- 次要结局包括死亡率和PICU住院时长。
临床怎么用
- 对PICU患儿使用应激性溃疡预防应权衡消化道出血获益与院内肺炎及死亡风险。
- 观察性研究提示的风险增加需在临床试验中进一步验证,临床决策应结合个体风险评估。
局限性
- 纳入研究以观察性研究为主(13项观察性研究 vs 4项随机对照试验),可能存在混杂偏倚。
- 死亡风险关联在剔除一项大型研究后不再显著,提示结果稳健性不足。
- PICU住院时长分析异质性高(I2=89.8%)。
- 消化道出血风险分析存在中等异质性(I2=62%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the associations of stress ulcer prophylaxis with gastrointestinal (GI) bleeding, nosocomial pneumonia (NP), mortality, and length of stay in the pediatric intensive care unit (PICU). STUDY DESIGN: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies in the English language assessing the effects of proton pump inhibitors and histamine-2 receptor antagonists on patients in the PICU published before October 2018 from the PubMed, Embase, CINAHL, and Cochrane Central Register of Controlled Trials databases. A random-effects Mantel-Haenszel risk difference (MHRD) model was used to pool all the selected studies for meta-analysis. Primary outcomes were the incidences of GI bleeding and NP. Secondary outcomes included mortality and length of PICU stay. RESULTS: Seventeen studies (4 RCTs and 13 observational studies) with a total of 340 763 patients were included. The overall incidence of GI bleeding was 15.2%. There was no difference in the risk of GI bleeding based on stress ulcer prophylaxis status (MHRD, 5.0%; 95% CI, -1.0% to 11.0%; I2 = 62%). There was an increased risk of NP in patients who received stress ulcer prophylaxis compared with those who did not (MHRD, 5.3%; 95% CI, 3.5%-7.0%; I2 = 0%). An increased risk of mortality was seen in patients receiving stress ulcer prophylaxis (MHRD, 2.1%; 95% CI, 2.0%-2.2%; I2 = 0%), although this association was no longer found when 1 large study was removed in a sensitivity analysis. There was no statistically significant difference in length of PICU stay between the groups (standardized mean difference, 0.42 days; 95% CI, -0.16 to 1.01 days; I2 = 89.8%). CONCLUSIONS: Stress ulcer prophylaxis does not show a clear benefit in reducing GI bleeding or length of PICU stay. Observational studies suggest an increased risk of NP and mortality with stress ulcer prophylaxis, which remains to be validated in clinical trials.
引用
- Yao DWJ, Ong C, Eales NM, et al. Reassessing the Use of Proton Pump Inhibitors and Histamine-2 Antagonists in Critically Ill Children: A Systematic Review and Meta-Analysis. J Pediatr. 2020. PMID: 32916144. doi:10.1016/j.jpeds.2020.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。